Expertise in
14
conditions

Dr. David K. Goebel

Hematology | Oncology
Alliance Healthcare Services Inc.
916 11th St, 
Portsmouth, OH 
Accepting New Patients
Expertise in
14
conditions
Alliance Healthcare Services Inc.
916 11th St, 
Portsmouth, OH 

Overview

David Goebel is a Hematologist and an Oncologist practicing medicine in Portsmouth, Ohio.

Dr. Goebel is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Multiple Myeloma, Inflammatory Breast Cancer, and Angiosarcoma.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 13 clinical trials. Dr. Goebel is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in OH

Hospital Affiliations

King's Daughters' Medical Center
Kings Daughters Medical Center Ohio

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Alliance Healthcare Services Inc.
916 11th St, Portsmouth, OH 45662

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
View 9 Less Clinical Trials

2 Total Publications

Clinician perspectives on delivering primary and specialty palliative care in community oncology practices.
Clinician perspectives on delivering primary and specialty palliative care in community oncology practices.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: March 21, 2024
Similar Doctors
Expertise in
58
conditions
Dr. Tsuyoshi Inoshita
Hematology | Oncology
Expertise in
58
conditions
Dr. Tsuyoshi Inoshita
Hematology | Oncology
Referral may be required

Kings Daughters Med Ctr Jackson Med Specialties

14395 State Route 93, 
Jackson, OH 
 (28.1 miles away)
606-324-2600
Languages Spoken:
English, Japanese
See accepted insurances
Accepting New Patients

Tsuyoshi Inoshita is a Hematologist and an Oncologist practicing medicine in Jackson, Ohio. Dr. Inoshita is highly rated in 58 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer. Dr. Inoshita is currently accepting new patients.

Expertise in
29
conditions
Dr. Chad J. Tarabolous
Hematology | Oncology
Expertise in
29
conditions
Dr. Chad J. Tarabolous
Hematology | Oncology
Referral may be required

Bellefonte Physician Services Inc.

100 Bellefonte Dr, 
Grayson, KY 
 (28.6 miles away)
606-329-9335
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chad Tarabolous is a Hematologist and an Oncologist practicing medicine in Grayson, Kentucky. Dr. Tarabolous is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Lung Cancer. Dr. Tarabolous is currently accepting new patients.

Expertise in
51
conditions
Dr. Galena Salem
Hematology | Oncology
Expertise in
51
conditions
Dr. Galena Salem
Hematology | Oncology
Referral may be required

Kings Daughters Medcial Specialties Inc

617 23rd St Ste 19, 
Ashland, KY 
 (26.1 miles away)
606-325-2221
Languages Spoken:
English, Russian, Ukrainian
See accepted insurances
Accepting New Patients

Galena Salem is a Hematologist and an Oncologist practicing medicine in Ashland, Kentucky. Dr. Salem is highly rated in 51 conditions, according to our data. Her clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Non-Hodgkin Lymphoma, Familial Colorectal Cancer, Clear Cell Sarcoma, and Bone Marrow Transplant. Dr. Salem is currently accepting new patients.

Frequently Asked Questions about Dr. David K. Goebel

How do I make an appointment with Dr. David K. Goebel?

You can book an appointment with Dr. David K. Goebel by calling their office at 740-353-4884. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David K. Goebel a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David K. Goebel is classified as an Advanced expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David K. Goebel specialize in?

While Dr. David K. Goebel is a Hematology, they have specific expertise in Paget Disease of the Breast, Multiple Myeloma, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. David K. Goebel participate in research or clinical trials?

Yes. Dr. David K. Goebel has published 2 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. David K. Goebel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David K. Goebel accept my insurance?

Dr. David K. Goebel accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 740-353-4884 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goebel's expertise for a condition
ConditionClose
      View All 14 Advanced Conditions
      View All 79 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile